Ok, I just read the Seeking Alpha transcript from Redhill... The only thing mentioned about R-103 was this:
Scott Henry - Roth Capital
Okay, perfect. And final question, any thoughts on the partnership front, what should we be thinking about as far as, I know you are working on RHB-101, but how should we think about the partnership front over the next kind of 6 to 12 months?
Dror Ben Asher - CEO
Right, this is one of most important tasks; right now the most important item here is the divestment of non-core assets. All other non-core assets, the non-core assets are those that are not within our therapeutic focus of GI and inflammation. And those are specifically RHB-103 RIZAPORT for migraine and RHB-101 which is a cardio drug. RHB-101 is a legacy drug, we have recently announced last month, we announced that we are in discussions for both of these product for out-licensing, which we hope to complete in the first half of 2015.
So this is the highest priority, obviously discussion on other product, but Redhill is in the fortunate position that we are able to complete our Phase III studies with our existing results, resources and as time goes by obviously the value of the assets keeps going up. So we are in no rush to out-license everything else and so there is obviously in track.
I am guessing that you are talking about the wording of "divestment of non-core assets" of which RHB-103 is one. It simply means that they are looking to out license it, and hope to have that completed in the first half of 2015... It really doesn't mean anything right now. While IGXT is going up slowly right now, for whatever reason, people are still waiting for a new PDUFA date!
